BIIB · Biogen Inc
United States · RS rating 96 · As of 2026-10-14
| Price | 232.83 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 92 / 87 / 91 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 41 / 59 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -110.4% |
| Sales growth Q/Q | -10.1% |
| Distance from 52-week high | +0.0% |
| Market cap (USD) | $27.6B |